CN110121358A - 一种预防和治疗肺纤维化的方法 - Google Patents

一种预防和治疗肺纤维化的方法 Download PDF

Info

Publication number
CN110121358A
CN110121358A CN201780078132.8A CN201780078132A CN110121358A CN 110121358 A CN110121358 A CN 110121358A CN 201780078132 A CN201780078132 A CN 201780078132A CN 110121358 A CN110121358 A CN 110121358A
Authority
CN
China
Prior art keywords
plasminogen
fibrosis
subject
drug
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780078132.8A
Other languages
English (en)
Inventor
李季男
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Talengen Institute of Life Sciences Co Ltd
Original Assignee
Talengen Institute of Life Sciences Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Talengen Institute of Life Sciences Co Ltd filed Critical Talengen Institute of Life Sciences Co Ltd
Publication of CN110121358A publication Critical patent/CN110121358A/zh
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482Serine endopeptidases (3.4.21)
    • A61K38/484Plasmin (3.4.21.7)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/04Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21Serine endopeptidases (3.4.21)
    • C12Y304/21007Plasmin (3.4.21.7), i.e. fibrinolysin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

本发明涉及一种预防和治疗肺纤维化的方法,包括给药受试者有效量的纤溶酶原。

Description

PCT国内申请,说明书已公开。

Claims (41)

  1. PCT国内申请,权利要求书已公开。
CN201780078132.8A 2016-12-15 2017-06-19 一种预防和治疗肺纤维化的方法 Pending CN110121358A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2016/110174 2016-12-15
CN2016110174 2016-12-15
PCT/CN2017/089057 WO2018107697A1 (zh) 2016-12-15 2017-06-19 一种预防和治疗肺纤维化的方法

Publications (1)

Publication Number Publication Date
CN110121358A true CN110121358A (zh) 2019-08-13

Family

ID=62557850

Family Applications (4)

Application Number Title Priority Date Filing Date
CN201780078166.7A Pending CN110139668A (zh) 2016-12-15 2017-06-19 一种预防和治疗肝纤维化的方法
CN201780078132.8A Pending CN110121358A (zh) 2016-12-15 2017-06-19 一种预防和治疗肺纤维化的方法
CN201780078123.9A Pending CN110114080A (zh) 2016-12-15 2017-06-19 一种预防和治疗皮肤纤维化的方法
CN201780078169.0A Pending CN110191718A (zh) 2016-12-15 2017-06-19 一种预防和治疗组织器官纤维化的方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201780078166.7A Pending CN110139668A (zh) 2016-12-15 2017-06-19 一种预防和治疗肝纤维化的方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN201780078123.9A Pending CN110114080A (zh) 2016-12-15 2017-06-19 一种预防和治疗皮肤纤维化的方法
CN201780078169.0A Pending CN110191718A (zh) 2016-12-15 2017-06-19 一种预防和治疗组织器官纤维化的方法

Country Status (7)

Country Link
US (4) US11071772B2 (zh)
EP (4) EP3556395A4 (zh)
JP (4) JP7313058B2 (zh)
CN (4) CN110139668A (zh)
CA (4) CA3046666A1 (zh)
TW (6) TWI734798B (zh)
WO (5) WO2018107698A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110831668A (zh) * 2017-06-23 2020-02-21 普罗米蒂克生物治疗公司 与pai-1过表达相关的病状的血纤维蛋白溶酶原治疗

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7313058B2 (ja) 2016-12-15 2023-07-24 タレンゲン インターナショナル リミテッド 組織器官の繊維化を予防及び治療するための方法
CN111344004A (zh) 2017-06-19 2020-06-26 泰伦基国际有限公司 一种调控glp-1/glp-1r 的方法和药物
CA3167593A1 (en) * 2020-02-11 2021-08-19 Jinan Li Method and drug for treating viral pneumonia
WO2023008283A1 (ja) 2021-07-30 2023-02-02 花王株式会社 パンツ型吸収性物品
CN114984032B (zh) * 2022-06-27 2023-07-07 四川大学 Dna四面体框架核酸-绿原酸复合物及其在制备治疗肝纤维化的药物中的用途

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040043026A1 (en) * 2002-05-13 2004-03-04 Tai-Lan Tuan Treatment and prevention of abnormal scar formation in keloids and other cutaneous or internal wounds or lesions
CN1768138A (zh) * 2002-02-06 2006-05-03 N-酶生物技术有限公司 在微生物中生产重组蛋白质的方法
WO2015026494A2 (en) * 2013-08-20 2015-02-26 Trustees Of Dartmouth College Methods for treating tissue fibrosis
CN105705520A (zh) * 2013-08-13 2016-06-22 赛诺菲 纤溶酶原激活剂抑制剂-1(pai-1)的抗体及其用途
CN106029884A (zh) * 2014-02-21 2016-10-12 安斯泰来制药株式会社 新型抗人pai-1抗体

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4645668A (en) * 1983-08-04 1987-02-24 Biospecifics, Nv Method for the prevention and treatment of scars with enzymes
GB8721951D0 (en) 1987-09-18 1987-10-28 Thrombosis Research Trust Organic compounds
EP1516628B1 (en) 1995-07-27 2013-08-21 Genentech, Inc. Stable isotonic lyophilized protein formulation
EP0910571B1 (en) * 1996-05-03 2005-07-20 Abbott Laboratories Novel antiangiogenic peptides, polynucleotides encoding same and methods for inhibiting angiogenesis
EP1001985A1 (en) 1997-06-26 2000-05-24 Karolinska Innovations AB Kringle domains 1-5 of plasminogen, capable of modulating angiogenesis in vivo
AU5571799A (en) 1998-08-20 2000-03-14 University Of Vermont And State Agricultural College, The Angiogenesis inhibitors and uses thereof
US7763580B2 (en) 1999-01-05 2010-07-27 University Of Utah Research Foundation Methods for treating conditions associated with the accumulation of excess extracellular matrix
AU2002239414A1 (en) 2000-11-02 2002-05-27 Bristol-Myers Squibb Company Modified plasminogen related peptide fragments and their use as angiogenesis inhibitors
MXPA00011713A (es) 2000-11-28 2002-05-31 Tgt Lab S A De C V Vectores recombinantes virales y no virales conteniendo el gen humano del activador de plasminogeno derivado de urocinasa y su utilidad en el tratamiento de diversos tipos de fibrosis hepatica, renal, pulmonar, pancreatica, cardiaca y cicatrices hipe
US7067492B2 (en) 2001-09-06 2006-06-27 Omnio Ab Method of promoting healing of a tympanic membrane perforation
DE10390418D2 (de) * 2002-02-06 2005-01-13 N Zyme Biotec Gmbh Verfahren zur Herstellung von rekombinanten Proteinen in Mikroorganismen
US7348351B2 (en) 2002-12-10 2008-03-25 Wyeth Substituted 3-alkyl and 3-arylalkyl 1H-indol-1yl acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
US20050250694A1 (en) 2003-10-10 2005-11-10 Ma Jian-Xing Compounds useful in inhibiting vascular leakage, inflammation and fibrosis and methods of making and using same
CA2577782A1 (en) 2004-08-23 2006-03-02 Wyeth Pyrrolo-naphthyl acids as pai-1 inhibitors
CN101563100B (zh) * 2006-08-28 2013-08-07 李季男 用于预防和治疗牙周病、改善牙周创伤愈合以及促进口腔健康的新药物靶标
US20100080773A1 (en) 2008-09-26 2010-04-01 Sdg, Inc. Orally Bioavailable Lipid-Based Constructs
PT2220221E (pt) 2007-11-29 2015-04-16 Grifols Therapeutics Inc Plasmina modificada de forma recombinante
US8697840B2 (en) * 2008-03-05 2014-04-15 Board Of Regents, The University Of Texas System Peptide inhibition of lung epithelial apoptosis and pulmonary fibrosis
CN102482338B (zh) 2009-07-10 2016-09-28 斯路姆基因公司 纤溶酶原和纤溶酶的变体
CN101628113B (zh) 2009-08-18 2012-01-04 南京农业大学 蚯蚓纤溶酶抗肝纤维化的应用
CA2779905A1 (en) 2009-11-07 2011-05-12 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2011139974A2 (en) * 2010-05-03 2011-11-10 Abbott Laboratories Anti-pai-1 antibodies and methods of use thereof
CN102121023B (zh) 2010-12-22 2012-07-04 中山大学 突变型人纤溶酶原kringle5及其制备方法及应用
KR20140015289A (ko) * 2011-01-05 2014-02-06 쓰롬보제닉스 엔.브이. 플라스미노겐 및 플라스민 변이체
CN102154253A (zh) 2011-01-06 2011-08-17 郑州大学 具有抑制血小板凝集功能的微小纤溶酶原突变体及其制备方法和用途
US9655973B2 (en) 2012-03-09 2017-05-23 Vascular Biosciences Orally active, cell-penetrating homing peptide and methods of using same
KR101467109B1 (ko) 2013-07-10 2014-12-01 영남대학교 산학협력단 Bix02189 화합물을 유효성분으로 포함하는 폐섬유증 예방 또는 치료용 조성물
TW201734054A (zh) 2013-08-13 2017-10-01 賽諾菲公司 胞漿素原活化素抑制劑-1(pai-1)之抗體及其用途
CN104371019B (zh) 2013-08-13 2019-09-10 鸿运华宁(杭州)生物医药有限公司 一种能与glp-1r特异性结合的抗体及其与glp-1的融合蛋白质
AU2015367185B2 (en) 2014-12-19 2021-05-27 Prometic Bio Therapeutics, Inc. Pharmaceutical composition comprising plasminogen and uses thereof
TWI801331B (zh) 2015-11-03 2023-05-11 美商波麥堤克生物治療股份有限公司 纖維蛋白溶酶原缺乏症之纖維蛋白溶酶原替代療法
CN106890318A (zh) 2015-12-18 2017-06-27 深圳瑞健生命科学研究院有限公司 一种预防和治疗糖尿病性心脏病的新方法
CN106890320A (zh) 2015-12-18 2017-06-27 深圳瑞健生命科学研究院有限公司 一种用于预防或治疗急性及慢性血栓的方法
CN108463236A (zh) 2015-12-18 2018-08-28 泰伦基国际有限公司 一种预防或治疗放射性和化学性损伤的方法
US11400142B2 (en) 2015-12-18 2022-08-02 Talengen International Limited Treatment of diabetic nerve injury comprising administering plasminogen
EP3395359B1 (en) 2015-12-18 2023-11-01 Talengen International Limited Plasminogen for use in preventing or treating acute thrombosis and chronic thrombosis
DK3391902T3 (da) 2015-12-18 2023-11-20 Talengen Int Ltd Plasminogen til anvendelse i behandlingen af diabetisk angiokardiopati
CN106890324A (zh) 2015-12-18 2017-06-27 深圳瑞健生命科学研究院有限公司 一种预防和治疗糖尿病肾病的方法
CN110114079A (zh) 2016-12-15 2019-08-09 泰伦基国际有限公司 一种预防和治疗肥胖症的方法和药物
WO2018107687A1 (zh) * 2016-12-15 2018-06-21 深圳瑞健生命科学研究院有限公司 一种预防和治疗高脂血症的方法
CN110366427A (zh) * 2016-12-15 2019-10-22 泰伦基国际有限公司 一种预防和治疗病理性肾组织损伤的方法
CA3047175A1 (en) * 2016-12-15 2018-06-21 Talengen International Limited Method for mitigating heart disease
EP3556384B1 (en) 2016-12-15 2024-04-10 Talengen International Limited Plasminogen for use in treating diabetes
JP7313058B2 (ja) 2016-12-15 2023-07-24 タレンゲン インターナショナル リミテッド 組織器官の繊維化を予防及び治療するための方法
CN111344004A (zh) * 2017-06-19 2020-06-26 泰伦基国际有限公司 一种调控glp-1/glp-1r 的方法和药物

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1768138A (zh) * 2002-02-06 2006-05-03 N-酶生物技术有限公司 在微生物中生产重组蛋白质的方法
US20040043026A1 (en) * 2002-05-13 2004-03-04 Tai-Lan Tuan Treatment and prevention of abnormal scar formation in keloids and other cutaneous or internal wounds or lesions
CN105705520A (zh) * 2013-08-13 2016-06-22 赛诺菲 纤溶酶原激活剂抑制剂-1(pai-1)的抗体及其用途
WO2015026494A2 (en) * 2013-08-20 2015-02-26 Trustees Of Dartmouth College Methods for treating tissue fibrosis
CN106029884A (zh) * 2014-02-21 2016-10-12 安斯泰来制药株式会社 新型抗人pai-1抗体

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ASISH K.GHOSH 等: "PAI-l in tissue fibrosis1", 《JOURNAL OF CELLULAR PHYSIOLOGY》 *
ZHENHUA ZHOU 等: "The Development of Bleomycin-Induced Pulmonary Fibrosis in Mice Deficient for Components of the Fibrinolytic System", 《AMERICAN JOURNAL OF PATHOLOG》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110831668A (zh) * 2017-06-23 2020-02-21 普罗米蒂克生物治疗公司 与pai-1过表达相关的病状的血纤维蛋白溶酶原治疗
CN110831668B (zh) * 2017-06-23 2024-04-12 普罗米蒂克生物治疗公司 与pai-1过表达相关的病状的血纤维蛋白溶酶原治疗

Also Published As

Publication number Publication date
JP2020511413A (ja) 2020-04-16
EP3556395A4 (en) 2020-07-22
TW201822790A (zh) 2018-07-01
TWI657823B (zh) 2019-05-01
CN110139668A (zh) 2019-08-16
CA3046669A1 (en) 2018-06-21
JP2020502132A (ja) 2020-01-23
US11219669B2 (en) 2022-01-11
EP3556380A4 (en) 2020-05-13
US20190314467A1 (en) 2019-10-17
EP3556389A4 (en) 2020-07-15
US20190314466A1 (en) 2019-10-17
EP3556395A1 (en) 2019-10-23
TW201822783A (zh) 2018-07-01
EP3556382A1 (en) 2019-10-23
JP7313058B2 (ja) 2023-07-24
TWI734798B (zh) 2021-08-01
CN110191718A (zh) 2019-08-30
TW201822796A (zh) 2018-07-01
JP7213552B2 (ja) 2023-01-27
TWI670075B (zh) 2019-09-01
JP7213553B2 (ja) 2023-01-27
US11071772B2 (en) 2021-07-27
WO2018107697A1 (zh) 2018-06-21
CA3047174A1 (en) 2018-06-21
US20190314468A1 (en) 2019-10-17
US20190365872A1 (en) 2019-12-05
CA3046666A1 (en) 2018-06-21
TWI752044B (zh) 2022-01-11
JP2020512288A (ja) 2020-04-23
CA3046671A1 (en) 2018-06-21
WO2018107696A1 (zh) 2018-06-21
EP3556380A1 (en) 2019-10-23
EP3556382A4 (en) 2020-12-09
CA3046671C (en) 2023-08-08
CN110114080A (zh) 2019-08-09
EP3556389A1 (en) 2019-10-23
TW201822789A (zh) 2018-07-01
TW202123955A (zh) 2021-07-01
JP2020502133A (ja) 2020-01-23
US11154595B2 (en) 2021-10-26
WO2018107698A1 (zh) 2018-06-21
WO2018107693A1 (zh) 2018-06-21
TW201822795A (zh) 2018-07-01
WO2018107694A1 (zh) 2018-06-21

Similar Documents

Publication Publication Date Title
CN110121358A (zh) 一种预防和治疗肺纤维化的方法
CN110167583A (zh) 一种治疗冠状动脉粥样硬化及其并发症的方法
WO2018107695A1 (zh) 一种预防和治疗肾纤维化的方法
CN108210897A (zh) 预防和治疗肺纤维化的药物及其用途
CN108463236A (zh) 一种预防或治疗放射性和化学性损伤的方法
CN108210893A (zh) 预防和治疗肾纤维化的药物及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination